Leading Sinclair's global Commercial Excellence activities: Strategy, pricing and commercial policies, internal consulting, sales force effectiveness and distribution strategies.

Led Sinclair's operational and strategic marketing, integrated across injectables and energy-based devices (EBD). Global responsibility for Sinclair brands (including Ellansé, MaiLi, Lanluma, Primelase, and V-series), global customer training and KOL development, digital marketing, and global events such as IMCAS, AMWC, and WEM.

Global franchise leader of Galderma’s aesthetic neuromodulator franchise. Global responsibility for the Dysport, Azzalure, Alluzience and Relfydess brands. Led the successful global launch of Alluzience, a first-in-class liquid neuromodulator; doubled the sales of Dysport/Azzalure; and shaped Relfydess clinical studies to demonstrate market-leading duration.

Responsible for Ipsen's Dysport aesthetics franchise. Led the global aesthetic marketing team, and oversaw Ipsen's global strategic alliance with Galderma for Dysport/Azzalure. Shaped the SmPC of Alluzience for maximum promotional impact.

Founded a parallel trading company in the European medical aesthetics market. Developed commercial concept, secured financing, built key team, and set up commercial partnerships.

Led Allergan Medical Aesthetics's business in Eastern Europe. P&L responsibility; sales deployment and execution; marketing execution. Lead team of 45 in-country staff members.

Led Allergan’s corporate priority programme to establish subsidiaries in South Africa and Russia. Led 16 functional workstreams involving over 100 direct project participants.

Responsible for Allergan Medical Aesthetic's commercial strategy in Europe, including pricing, discounting, portfolio strategy and channel strategy. Launched Juvéderm Ultra.

Principal consultant advising IQVIA clients in the pharmaceutical industry. Led IQVIA's UK Product and Portfolio Development Practice.

Led department responsible for driving commercial improvement in ALK-Abelló's international subsidiaries.

Reported to the CEO of ALK-Abelló. Responsible for leading key strategic projects, including a corporate strategy review, a global cost-effectiveness programme, and a product portfolio review.

Strategic adviser to major global companies, focusing on Life Sciences: Pharmaceuticals, Biotech, Medical Devices and Medical Equipment. Advised clients on strategic marketing, alliance building, business development and M&A. Led McKinsey consulting teams.